ORAL ACYCLOVIR IN NEONATAL HERPEX SIMPLEX

点击翻译按钮获取中文摘要

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This study will evaluate the efficacy of long-term suppressive therapy with oral acyclovir in infants with neonatal herpes infections limited to the skin, eye, or mouth (SEM). It will determine if suppressive oral acyclovir therapy improves neurologic outcome in infants following SEM disease. Additionally, it will determine if continuous administration of oral acyclovir suspension suppresses recurrent skin lesions in infants following SEM disease. It will confirm the safety of long-term administration of oral acyclovir therapy in a cohort of infants with SEM disease. The significance of positive CSF PCR results at the time of cutaneous recurrences will be assessed, and the development of viral variants resistant to acyclovir monitored and characterized. Finally, the effects of suppressive acyclovir therapy on issues of pharmocoeconomics and family infrastructure will be assessed and quantitated. The GCRC is utilized by providing clinical space, nursing staff, funding specialized testing and laboratory support.